esc

Type at least two characters to start searching.

↑↓ select↵ openesc close

Share

Export Citation

APA
MLA
Chicago
Harvard
Vancouver
BIBTEX
RIS
Universitas Hasanuddin
Research output:Contribution to journal›Article›peer-review

Rhizomes as Multi-Target Pharmacological Platforms Against Tauopathy: Neuro-Metabolic Crosstalk, Drug-Likeness, and Translational Challenges

Setiawan A.W.

Pharmaceuticals

Q1
Published: 2026Citations: 1

Abstract

Tauopathies, including Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal lobar degeneration with tau pathology, are unified by pathogenic tau misfolding, post-translational modification, aggregation, and network-level spread. Yet decades of drug development that predominantly pursued single nodes (e.g., one kinase, one aggregation inhibitor, one monoclonal antibody epitope) have repeatedly delivered late-stage disappointments, underscoring a central lesson: tauopathy behaves less like a linear pathway and more like a coupled system of proteostasis failure, neuroinflammation, synaptic-mitochondrial stress, and metabolic dysregulation. This review examines rhizomes (notably Zingiberaceae genera such as Curcuma, Zingiber, Alpinia, Kaempferia, and Boesenbergia) as chemically diverse “multi-target platforms” whose bioactives can engage several tau-relevant nodes simultaneously. We synthesise evidence across tau phosphorylation (GSK-3β/CDK5 and upstream stress signalling), tau aggregation and seeding, autophagy-lysosome and proteasome pathways, redox-mitochondrial resilience, neuroinflammatory circuits (NF-κB/NLRP3), and neuro-metabolic signalling (insulin-PI3K-AKT, AMPK-mTOR). A translational lens is applied throughout, focusing on drug-likeness and CNS multiparameter optimisation; BBB permeability and efflux; metabolism and bioavailability constraints; and formulation strategies (nanoparticles, phytosomes, engineered exosomes) that may render rhizome-derived scaffolds more clinically plausible. We conclude that rhizomes offer credible mechanistic hypotheses for tau modulation, but progress depends on rigorous standardisation, realistic exposure matching, biomarker-driven study design, and a shift from “single-compound optimism” to network pharmacology with translational discipline.

Access to Document

10.3390/ph19050792

Other files and links

Fingerprint

Progressive supranuclear palsySciences
Corticobasal degenerationSciences
NeuroscienceSciences
TauopathySciences
Computational biologySciences
ProteostasisSciences
Frontotemporal dementiaSciences
Drug discoverySciences
BiologySciences
BioinformaticsSciences
Frontotemporal lobar degenerationSciences
AutophagySciences
NeurodegenerationSciences
MedicineSciences
Drug developmentSciences
DiseaseSciences
Translational medicineSciences
Precision medicineSciences
Systems biologySciences
GatingSciences
Computer scienceSciences
ChemistrySciences
Systems pharmacologySciences
ProteasomeSciences
PharmacologySciences
Approved drugSciences